 ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 headwinds. Unfortunately, the healthcare sector is experiencing some selling pressure after the outcome of the U.S. presidential election, and ADMA is moving closer to 52-week lows. 